HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: ps.051750905v1 14/12/3135    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seeliger, M. A. Articles by Kuriyan, J. Search for Related Content PubMed PubMed Citation Articles by Seeliger, M. A. Articles by Kuriyan, J. Social Bookmarking                   What's this?

FOR THE RECORD

High yield bacterial expression of active c-Abl and c-Src tyrosine kinases

¹ Howard Hughes Medical Institute, and ² Department of Molecular and Cell Biology and Department of Chemistry, University of California, Berkeley, California 94720, USA
³ Physical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA

(RECEIVED August 3, 2005; FINAL REVISION September 2, 2005; ACCEPTED September 4, 2005)

The Abl and Src tyrosine kinases are key signaling proteins that are of considerable interest as drug targets in cancer and many other diseases. The regulatory mechanisms that control the activity of these proteins are complex, and involve large-scale conformational changes in response to phosphorylation and other modulatory signals. The success of the Abl inhibitor imatinib in the treatment of chronic myelogenous leukemia has shown the potential of kinase inhibitors, but the rise of drug resistance in patients has also shown that drugs with alternative modes of binding to the kinase are needed. The detailed understanding of mechanisms of protein–drug interaction and drug resistance through biophysical methods demands a method for the production of active protein on the milligram scale. We have developed a bacterial expression system for the kinase domains of c-Abl and c-Src, which allows for the quick expression and purification of active wild-type and mutant kinase domains by coexpression with the YopH tyrosine phosphatase. This method makes practical the use of isotopic labeling of c-Abl and c-Src for NMR studies, and is also applicable for constructs containing the SH2 and SH3 domains of the kinases.

Keywords: Src; Abl; imatinib; tyrosine kinases; biophysical methods; bacterial expression; NMR

Article published online ahead of print. Article and publication date are at http://www.proteinscience.org/cgi/doi/10.1110/ps.051750905.

Reprint requests to: John Kuriyan, Department of Molecular and Cell Biology, 16 Barker Hall, University of California, Berkeley, CA 94720-3202, USA; e-mail: kuriyan{at}berkeley.edu; fax: (510) 643-2352.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. N. Betts, P. van der Geer, and E. A. Komives Structural and Functional Consequences of Tyrosine Phosphorylation in the LRP1 Cytoplasmic Domain J. Biol. Chem., June 6, 2008; 283(23): 15656 - 15664. [Abstract] [Full Text] [PDF]

				M. A. Young, N. P. Shah, L. H. Chao, M. Seeliger, Z. V. Milanov, W. H. Biggs III, D. K. Treiber, H. K. Patel, P. P. Zarrinkar, D. J. Lockhart, et al. Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680 Cancer Res., January 15, 2006; 66(2): 1007 - 1014. [Abstract] [Full Text] [PDF]